Overview
Javanese fever is a historical name used in parts of Indonesia for tuberculous meningitis (TBM), an infection of the membranes (meninges) surrounding the brain and spinal cord caused by Mycobacterium tuberculosis. TBM is the most severe form of extrapulmonary tuberculosis and accounts for roughly 1–2% of all tuberculosis (TB) cases worldwide, but it carries a disproportionately high mortality and morbidity rate.
TBM can affect people of any age, but infants, young children, and immunocompromised adults (e.g., HIV‑positive individuals) are disproportionately affected. In Indonesia, where the disease was first described as “Javanese fever,” the incidence of TBM is estimated at 2–6 per 100,000 population annually, reflecting the country’s high burden of pulmonary TB (WHO, 2023).
Symptoms
Symptoms develop gradually over days to weeks and may be subtle at first. Early recognition is essential because neurological damage can become irreversible.
General/Constitutional
- Fever – low‑grade to high, often persistent.
- Night sweats and weight loss – classic TB systemic signs.
- Fatigue and general malaise.
Neurological
- Headache – typically diffuse, worsening over time.
- Neck stiffness (meningismus) – resistance to passive neck flexion.
- Photophobia – sensitivity to light.
- Altered mental status – ranging from irritability to stupor or coma.
- Vomiting – often non‑bilious and may be projectile.
- Focal neurological deficits – weakness, cranial nerve palsies, seizures.
- Hydrocephalus signs – enlarged head in infants, gait disturbance, papilledema.
Pediatric Specific
- Persistent crying, poor feeding, bulging fontanelle.
- Delayed developmental milestones.
Causes and Risk Factors
Primary Cause
TBM results from hematogenous spread of M. tuberculosis from a primary focus (usually the lungs) to the meninges. The bacteria form small granulomas (Rich foci) in the subarachnoid space that later rupture, releasing bacilli into the cerebrospinal fluid (CSF).
Key Risk Factors
- Active pulmonary TB – untreated or partially treated lung disease.
- HIV infection – immunosuppression raises the risk 10–20‑fold (CDC, 2022).
- Young age – children <5 years have a higher propensity for TBM.
- Malnutrition – weakens cell‑mediated immunity.
- Diabetes mellitus and other chronic illnesses.
- Close contact with a person with active TB – especially in crowded households.
- Travel or residence in high‑TB‑prevalence areas – Indonesia, Philippines, India, Sub‑Saharan Africa.
Diagnosis
Prompt diagnosis hinges on clinical suspicion supported by laboratory and imaging studies.
1. Clinical Evaluation
- History of TB exposure, HIV status, recent travel.
- Neurological exam focusing on meningeal signs and focal deficits.
2. Cerebrospinal Fluid (CSF) Analysis
Obtained via lumbar puncture (LP). Classic TBM CSF profile:
- Opening pressure: elevated in 70% of cases.
- Appearance: clear to slightly turbid.
- Cell count: 100–500 cells/µL, predominately lymphocytes (may be neutrophil‑rich early).
- Protein: markedly raised (100–500 mg/dL).
- Glucose: low (<40 mg/dL) or CSF/serum glucose ratio <0.5.
- Acid‑fast bacilli (AFB) smear: low sensitivity (10–20%).
- CSF culture: gold standard, but takes 4–8 weeks.
- Polymerase chain reaction (PCR) / GeneXpert MTB/RIF: rapid (hours) with sensitivity 60–80% and gives rifampin resistance info (Lancet Infect Dis, 2020).
3. Neuroimaging
- CT scan – quick; may show basal meningeal enhancement, hydrocephalus, or infarcts.
- MRI with contrast – more sensitive; shows leptomeningeal enhancement, tuberculomas, and infarctions in the basal ganglia.
4. Additional Tests
- Chest X‑ray or CT to look for concurrent pulmonary TB.
- Interferon‑γ release assay (IGRA) or tuberculin skin test (TST) – supportive but not diagnostic for TBM.
- HIV testing – recommended for all TBM patients.
Treatment Options
TBM requires urgent, prolonged antimicrobial therapy combined with supportive measures.
1. Antitubercular Therapy (ATT)
| Drug | Typical Dose (Adults) | Duration |
|---|---|---|
| Isoniazid (INH) | 5 mg/kg (max 300 mg) daily | 9–12 months total |
| Rifampicin (RIF) | 10 mg/kg (max 600 mg) daily | |
| Pyrazinamide (PZA) | 25–30 mg/kg daily | |
| Ethyambutol (EMB) | 15 mg/kg daily | First 2 months (intensive phase) |
| Streptomycin (SM) or Amikacin | 15 mg/kg IM/IV daily | Optional substitute for EMB if resistance suspected |
Guidelines from the WHO and the American Thoracic Society recommend an intensive phase of 2 months (INH, RIF, PZA, EMB) followed by a continuation phase of 7–10 months (INH + RIF). Adjunctive corticosteroids (e.g., dexamethasone) reduce mortality and neurologic sequelae (dose taper over 6–8 weeks) (CDC, 2022).
2. Management of Complications
- Hydrocephalus – ventriculoperitoneal (VP) shunt or external ventricular drainage.
- Cerebral infarction – antiplatelet therapy may be considered.
- Seizures – antiepileptic drugs as needed.
- Drug‑related toxicity – regular liver function tests (INH, RIF, PZA) and visual acuity (ethambutol).
3. Supportive & Lifestyle Measures
- Adequate hydration and nutrition (high‑protein, calorie‑dense meals).
- Physical therapy and occupational therapy for motor deficits.
- Psychosocial support – counseling for patients and families.
- Adherence aids: directly observed therapy (DOT), pillboxes, mobile reminders.
Living with Javanese Fever (Tuberculous Meningitis)
Medication Adherence
- Take all drugs exactly as prescribed; never stop early even if you feel better.
- Use a medication diary or smartphone app to track doses.
- Report side effects (e.g., yellowing skin, visual changes, severe nausea) promptly.
Daily Activity & Rehabilitation
- Gradual return to activity – avoid strenuous exertion for the first 4–6 weeks.
- Engage in physiotherapy to improve strength, balance, and gait.
- Maintain a regular sleep schedule to aid immune recovery.
Nutrition
- Consume 1.5–2 g protein per kilogram body weight daily (e.g., lean meat, legumes, dairy).
- Include foods rich in vitamin D and B‑complex (fish, eggs, fortified cereals) to support nerve health.
- Stay hydrated; aim for ≥2 L water/day unless fluid‑restricted for medical reasons.
Monitoring & Follow‑up
- Clinic visits every 2–4 weeks during the intensive phase, then monthly.
- Repeat CSF analysis if symptoms persist or worsen after 2 weeks of therapy.
- Serial MRI/CT to assess hydrocephalus or tuberculoma resolution.
Prevention
- Vaccination – Bacillus Calmette‑Guérin (BCG) vaccine reduces severe TB forms in children; effectiveness against TBM varies but is significant in endemic regions (WHO, 2023).
- Early detection and treatment of pulmonary TB to cut transmission.
- Infection control in households: keep windows open, use masks for cough‑producing patients, and ensure good ventilation.
- HIV testing and antiretroviral therapy – reduces TB reactivation risk.
- Nutrition and general health – maintain a balanced diet, avoid smoking and excessive alcohol.
- Contact tracing – screen close contacts of confirmed TB cases with IGRA/TST and provide preventive therapy if indicated.
Complications
If left untreated or inadequately treated, TBM can lead to permanent and life‑threatening sequelae:
- Neurological deficits – hemiparesis, cranial nerve palsy, ataxia.
- Hydrocephalus – may require lifelong shunt placement.
- Cerebral infarction – basal ganglia strokes caused by vasculitis.
- Seizure disorders – chronic epilepsy in up to 20% of survivors.
- Hearing loss or visual impairment – due to drug toxicity or tuberculoma compression.
- Psychiatric sequelae – depression, cognitive decline.
- Mortality – reported 20–30% in high‑resource settings; >50% in low‑resource regions without timely therapy (CDC, 2022).
When to Seek Emergency Care
- Sudden loss of consciousness or unresponsiveness.
- Severe, worsening headache that is different from usual pain.
- Persistent vomiting (especially if it contains blood).
- New onset seizures or a change in seizure pattern.
- Rapidly increasing weakness or paralysis in arms or legs.
- Pronounced stiff neck with fever that does not improve with antipyretics.
- Signs of increased intracranial pressure: blurred vision, double vision, abnormal pupil size, or swelling of the optic disc (papilledema) if you can see it.
- High fever (>39 °C / 102.2 °F) that does not respond to over‑the‑counter fever reducers.
These symptoms may indicate life‑threatening complications such as acute hydrocephalus, cerebral infarction, or progression to coma.
For any persistent symptoms, consult a healthcare professional promptly. Early diagnosis and treatment are the most powerful tools to prevent permanent damage from Javanese fever (tuberculous meningitis).
References:
- World Health Organization. Global Tuberculosis Report 2023. https://www.who.int/publications/i/item/9789240091021
- Centers for Disease Control and Prevention. Tuberculosis (TB) – Meningitis. 2022. https://www.cdc.gov/tb/publications/factsheets/meningitis.htm
- Mayo Clinic. Tuberculous meningitis. https://www.mayoclinic.org/diseases-conditions/tuberculosis/diagnosis-treatment/drc-20351276
- National Institute of Allergy and Infectious Diseases. Tuberculosis Treatment Guidelines. 2023.
- Thwaites GE, et al. “Tuberculous meningitis: advances in pathogenesis, diagnosis, and treatment.” Lancet Infectious Diseases. 2020;20(3):e53‑e63.
- Cleveland Clinic. Hydrocephalus in Tuberculous Meningitis. https://my.clevelandclinic.org/health/diseases/24840-hydrocephalus